Dose Response to Adjunctive Light Therapy in Citalopram-Treated Patients with Post-Stroke Depression

Søndergaard, Mette; Jarden, Jens Ole; Martiny, Klaus; Andersen, Grethe; Bech, Per

doi:10.1159/000092895

Cited by 25 publications

(12 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Out of the 12 trials included in online supplementary Table 3, 3 studies report no difference between the HAM-D 6 and HAM-D 17 , but all are statistically significant in showing that active treatment is superior to placebo. In Chouinard et al [27], Feiger et al [42], Bech et al [43], and Sondergaard et al [44], only the HAM-D 6 reached the level of statistical significance, whereas in the study by Ratti et al [45] the HAM-D 17 but not HAM-D 6 significantly discriminated between placebo and casopitant.…”

Section: Resultsmentioning

confidence: 99%

A Systematic Review of the Clinimetric Properties of the 6-Item Version of the Hamilton Depression Rating Scale (HAM-D<sub>6</sub>)

Timmerby

Andersen

Søndergaard

et al. 2017

Psychother Psychosom

View full text Add to dashboard Cite

Background: In a study aimed at identifying the items carrying information regarding the global severity of depression, the 6-item Hamilton Depression Rating Scale (HAM-D₆) was derived from the original 17-item version of the scale (HAM-D₁₇). Since then, the HAM-D₆ has been used in a wide range of clinical studies. We now provide a systematic review of the clinimetric properties of HAM-D₆ in comparison with those of HAM-D₁₇ and the Montgomery Asberg Depression Rating Scale (MADRS). Methods: We conducted a systematic search of the literature in PubMed, PsycInfo, and EMBASE databases in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline. Studies reporting data on the clinimetric validity of the HAM-D₆ and either the HAM-D₁₇ or MADRS in non-psychotic unipolar or bipolar depression were included in the synthesis. Results: The search identified 681 unique records, of which 51 articles met the inclusion criteria. According to the published literature, HAM-D₆ has proven to be superior to both HAM-D₁₇ and MADRS in terms of scalability (each item contains unique information regarding syndrome severity), transferability (scalability is constant over time and irrespective of sex, age, and depressive subtypes), and responsiveness (sensitivity to change in severity during treatment). Conclusions: According to the published literature, the clinimetric properties of HAM-D₆ are superior to those of both the HAM-D₁₇ and MADRS. Since the validity of HAM-D₆ has been demonstrated in both research and clinical practice, using the scale more consistently would facilitate translation of results from one setting to the other.

show abstract

Section: Resultsmentioning

confidence: 99%

A Systematic Review of the Clinimetric Properties of the 6-Item Version of the Hamilton Depression Rating Scale (HAM-D<sub>6</sub>)

Timmerby

Andersen

Søndergaard

et al. 2017

Psychother Psychosom

View full text Add to dashboard Cite

show abstract

“…Studies showed that the HAM-D 6 , but not the HAM-D 17 , sensitively discriminated between active drug and placebo [139,[147][148][149]. In Chouinard et al [147], brofaromine was statistically (p < 0.050) superior to placebo on the HAM-D 6 , but did not significantly differ from placebo on the HAM-D 17 .…”

Section: Differentiating Active Treatment From Placebomentioning

confidence: 99%

The Hamilton Rating Scales for Depression: A Critical Review of Clinimetric Properties of Different Versions

Carrozzino

Patierno

Fava

et al. 2020

Psychother Psychosom

172

126

View full text Add to dashboard Cite

The format of the original Hamilton Rating Scale for Depression (HAM-D) was unstructured: only general instructions were provided for rating individual items. Over the years, a number of modified versions of the HAM-D have been proposed. They differ not only in the number of items, but also in modalities of administration. Structured versions, including item definitions, anchor points and semi-structured or structured interview questions, were developed. This comprehensive review was conducted to examine the clinimetric properties of the different versions of the HAM-D. The aim was to identify the HAM-D versions that best display the clinimetric properties of reliability, validity, and sensitivity to change. The search was conducted on MEDLINE, Scopus, Web of Science, and PubMed, and yielded a total of 35,473 citations, but only the most representative studies were in-cluded. The structured versions of the HAM-D were found to display the highest inter-rater and test-retest reliability. The Clinical Interview for Depression and the 6-item HAM-D showed the highest sensitivity in differentiating active treatment from placebo. The findings indicate that the HAM-D is a valid and sensitive clinimetric index, which should not be discarded in view of obsolete and not clinically relevant psychometric criteria. The HAM-D, however, requires an informed use: unstructured forms should be avoided and the type of HAM-D version that is selected should be specified in the registration of the study protocol and in the methods of the trial. scale exceeds 21,000 on Scopus. Hamilton himself recommended, however, to use only the first 17 items of the HAM-D 21 since the last 4 symptoms (i.e., diurnal variation, depersonalization/derealization, paranoid and obsessional/compulsive symptoms) were either not considered part of the disease, or they were relatively uncommon, or they were not considered features related to depression severity [2,3]. Over the years, a number of modifications of the scale have been proposed and several versions of the HAM-D have been developed and come into use [4,5].

show abstract

“…Light therapy (LT) has expanded in application to other neuropsychiatric domains—some examples are to be found in studies of bipolar disorder (Benedetti, ), borderline personality disorder (Bromundt et al., ), Parkinson's disease (Martino, Freelance, & Willis, ; Videnovic et al., ), fibromyalgia (Burgess et al., )—and even to internal medicine, for example, insomnia in cirrhosis (De Rui et al., ) or post‐kidney transplantation (Burkhalter et al., ), depression in cystic fibrosis patients (Kopp et al., ), post‐stroke (Sondergaard, Jarden, Martiny, Andersen, & Bech, ) and cancer (Dallaspezia, Cantamessa, & Benedetti, ). Light probably does not treat the illness per se , but it can aid in reducing concomitant symptoms of poor sleep and daytime alertness.…”

Section: Where Are We Today?mentioning

confidence: 99%

Perspectives in affective disorders: Clocks and sleep

Wirz‐Justice

Benedetti

2019

Eur J of Neuroscience

View full text Add to dashboard Cite

Mood disorders are often characterised by alterations in circadian rhythms, sleep disturbances and seasonal exacerbation. Conversely, chronobiological treatments utilise zeitgebers for circadian rhythms such as light to improve mood and stabilise sleep, and manipulations of sleep timing and duration as rapid antidepressant modalities. Although sleep deprivation (“wake therapy”) can act within hours, and its mood‐elevating effects be maintained by regular morning light administration/medication/earlier sleep, it has not entered the regular guidelines for treating affective disorders as a first‐line treatment. The hindrances to using chronotherapeutics may lie in their lack of patentability, few sponsors to carry out large multi‐centre trials, non‐reimbursement by medical insurance and their perceived difficulty or exotic “alternative” nature. Future use can be promoted by new technology (single‐sample phase measurements, phone apps, movement and sleep trackers) that provides ambulatory documentation over long periods and feedback to therapist and patient. Light combinations with cognitive behavioural therapy and sleep hygiene practice may speed up and also maintain response. The urgent need for new antidepressants should hopefully lead to reconsideration and implementation of these non‐pharmacological methods, as well as further clinical trials. We review the putative neurochemical mechanisms underlying the antidepressant effect of sleep deprivation and light therapy, and current knowledge linking clocks and sleep with affective disorders: neurotransmitter switching, stress and cortico‐limbic reactivity, clock genes, cortical neuroplasticity, connectomics and neuroinflammation. Despite the complexity of multi‐system mechanisms, more insight will lead to fine tuning and better application of circadian and sleep‐related treatments of depression.

show abstract

Dose Response to Adjunctive Light Therapy in Citalopram-Treated Patients with Post-Stroke Depression

Cited by 25 publications

References 26 publications

A Systematic Review of the Clinimetric Properties of the 6-Item Version of the Hamilton Depression Rating Scale (HAM-D<sub>6</sub>)

A Systematic Review of the Clinimetric Properties of the 6-Item Version of the Hamilton Depression Rating Scale (HAM-D<sub>6</sub>)

The Hamilton Rating Scales for Depression: A Critical Review of Clinimetric Properties of Different Versions

Perspectives in affective disorders: Clocks and sleep

Contact Info

Product

Resources

About